Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
US Medicaid
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. Ac220 Compound
1. 950769-58-1
2. Ac220
3. Quizartinib (ac220)
4. Ac-220
5. Ac 220
6. Quizartinib Hcl
7. Ac010220
8. Quizartinib Freebase
9. Ac 010220
10. Asp-2689
11. 1-(5-(tert-butyl)isoxazol-3-yl)-3-(4-(7-(2-morpholinoethoxy)benzo[d]imidazo[2,1-b]thiazol-2-yl)phenyl)urea
12. 7la4o6q0d3
13. Chembl576982
14. N-(5-tert-butylisoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-ylethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea
15. Chebi:90217
16. 950769-58-1 (free Base)
17. Ac-010220
18. 1132827-21-4 (hcl)
19. 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-(4-{7-[2-(morpholin-4-yl)ethoxy]imidazo[2,1-b][1,3]benzothiazol-2-yl}phenyl)urea
20. 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[4-[6-(2-morpholin-4-ylethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl]urea
21. N-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea Dihydrochloride
22. Chembl2386811
23. 1-(5-(tert-butyl)isoxazol-3-yl)-3-(4-(7-(2-morpholinoethoxy)-benzo[d]imidazo[2,1-b]thiazol-2-yl)phenyl)urea
24. N-(5-(1,1-dimethylethyl)isoxazol-3-yl)-n'-(4-(7-(2-(morpholin-4-yl)ethoxy)imidazo(2,1- B)benzothiazol-2-yl)phenyl)urea
25. N-(5-(1,1-dimethylethyl)isoxazol-3-yl)-n'-(4-(7-(2-(morpholin-4-yl)ethoxy)imidazo(2,1-b)benzothiazol-2-yl)phenyl)urea
26. Urea, N-(5-(1,1-dimethylethyl)-3-isoxazolyl)-n'-(4-(7-(2-(4-morpholinyl)ethoxy) Imidazo(2,1-b)benzothiazol-2-yl)phenyl)-
27. Ac220 Compound
28. Ac220,quizartinib
29. Quizartinib [usan]
30. Quizartinib [usan:inn]
31. Quizartinibum
32. Unii-7la4o6q0d3
33. 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-(4-(7-(2-(morpholin-4-yl)ethoxy)imidazo(2,1-b)(1,3)benzothiazol-2-yl)phenyl)urea
34. N-(5-tert-butylisoxazol-3-yl)-n'-(4-(7-(2-(morpholin-4-yl)ethoxy)imidazo(2,1-b)(1,3)benzothiazol-2-yl)phenyl)urea
35. N-(5-tert-butylisoxazol-3-yl)-n'-[4-[7-[2-(morpholin-4-yl)ethoxy]imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl]urea
36. Quizartinib, 95%
37. Quizartinib, Ac220
38. Quizartinib, Free Base
39. Ac220 - Quizartinib
40. Quizartinib [mi]
41. Quizartinib; Plx3397
42. Quizartinib [inn]
43. Quizartinib (usan/inn)
44. Quizartinib, Ac010220
45. Schembl72923
46. Quizartinib [who-dd]
47. Mls006011240
48. Gtpl5658
49. Dtxsid70241746
50. Bcpp000443
51. Hms3244k09
52. Hms3244k10
53. Hms3244l09
54. Hms3265g09
55. Hms3265g10
56. Hms3265h09
57. Hms3265h10
58. Hms3654j20
59. Hms3743g21
60. Bcp02224
61. Bdbm50300690
62. Mfcd18074524
63. Nsc756647
64. Nsc799659
65. Nsc800857
66. S1526
67. Zinc43204002
68. Akos015891557
69. Bcp9000223
70. Ccg-264906
71. Cs-0211
72. Db12874
73. Nsc-756647
74. Nsc-799659
75. Nsc-800857
76. Sb16610
77. Ncgc00242493-01
78. Ncgc00242493-02
79. Ncgc00242493-07
80. As-16178
81. Hy-13001
82. Smr004703000
83. Ft-0687630
84. Sw218131-2
85. D09955
86. J-524214
87. Q7272714
88. Brd-k93918653-001-01-4
89. 3-(5-tert-butyl-1,2-oxazol-3-yl)-1-(4-{10-[2-(morpholin-4-yl)ethoxy]-7-thia-2,5-diazatricyclo[6.4.0.0^{2,6}]dodeca-1(12),3,5,8,10-pentaen-4-yl}phenyl)urea
90. N-(5-tert-butyl-isoxazol-3-yl)-n''-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea
91. N-(5-tert-butyl-isoxazol-3-yl)-n'-(4-(7-(2-(morpholin-4-ylethoxy)imidazo(2,1-b) (1,3)benzothiazol-2-yl)phenyl)urea
92. N-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea
93. N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-n'-[4-[7-[2-(4-morpholinyl)ethoxy]imidazo[2,1-b]benzothiazol-2-yl]phenyl]urea
| Molecular Weight | 560.7 g/mol |
|---|---|
| Molecular Formula | C29H32N6O4S |
| XLogP3 | 5.6 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 8 |
| Exact Mass | 560.22057470 g/mol |
| Monoisotopic Mass | 560.22057470 g/mol |
| Topological Polar Surface Area | 134 Ų |
| Heavy Atom Count | 40 |
| Formal Charge | 0 |
| Complexity | 849 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Treatment of acute myeloid leukaemia.
Treatment of acute myeloid leukaemia
In preclinical studies, Quizartinib demonstrated dose-dependent activity and favorable drug-like profiles in bioavailability, pharmacokinetics, cytochrome P450 (CYP) liability, and absorption, distribution, metabolism, excretion (ADME).
L01XE
L - Antineoplastic and immunomodulating agents
L01 - Antineoplastic agents
L01E - Protein kinase inhibitors
L01EX - Other protein kinase inhibitors
L01EX11 - Quizartinib
Quizartinib potently inhibits FLT3, a kinase that is mutated in approximately one-third of acute myeloid leukemia cases, and patients with FLT3 mutations are less responsive to traditional therapies.
Lee Fine Chem: Advancing Innovation and Quality in Intermediates, APIs, and Dosage Forms for Superior Pharmaceutical Solutions.


FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Quizartinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Leukemia, Myeloid, Acute.
Lead Product(s): Quizartinib,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 13, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Quizartinib,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Quizartinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Leukemia, Myeloid, Acute.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 13, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Quizartinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Quizartinib,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 13, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Quizartinib,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Quizartinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 13, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Quizartinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Liver Failure.
Lead Product(s): Quizartinib,Inapplicable
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 18, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Quizartinib,Inapplicable
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Assessment of Quizartinib Pharmacokinetic in Subjects With Severe Hepatic Impairment
Details : Quizartinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Liver Failure.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 18, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Quizartinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Quizartinib,Rufinamide
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 18, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Quizartinib,Rufinamide
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Quizartinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 18, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
VANFLYTA® (quizartinib) is an oral, highly potent, type II FLT3 inhibitor that selectively targets FLT3-ITD mutations and has been specifically developed for patients with FLT3-ITD positive AML.
Lead Product(s): Quizartinib,Cytarabine,Daunorubicin
Therapeutic Area: Oncology Brand Name: Vanflyta
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 10, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Quizartinib,Cytarabine,Daunorubicin
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
QuANTUM-Wild Phase 3 Trial of VANFLYTA® Begins in FLT3-ITD Negative AML
Details : VANFLYTA® (quizartinib) is an oral, highly potent, type II FLT3 inhibitor that selectively targets FLT3-ITD mutations and has been specifically developed for patients with FLT3-ITD positive AML.
Product Name : Vanflyta
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 10, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Quizartinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Leukemia.
Lead Product(s): Quizartinib,Daunorubicin,Idarubicin Hydrochloride,Cytarabine
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 29, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Quizartinib,Daunorubicin,Idarubicin Hydrochloride,Cytarabine
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
Details : Quizartinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Leukemia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 29, 2024

Details:
Quizartinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Leukemia, Myeloid, Acute.
Lead Product(s): Quizartinib,Etoposide,Dexrazoxane,Mitoxantrone,Cytarabine,Methotrexate,Daunorubicin,Fludarabine Phosphate
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Daiichi Sankyo
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 16, 2024

Lead Product(s) : Quizartinib,Etoposide,Dexrazoxane,Mitoxantrone,Cytarabine,Methotrexate,Daunorubicin,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Daiichi Sankyo
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Quizartinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Leukemia, Myeloid, Acute.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 16, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
VANFLYTA® (quizartinib) is an oral, highly potent, type II FLT3 inhibitor that selectively targets FLT3-ITD mutations and has been specifically developed for patients with FLT3-ITD positive AML.
Lead Product(s): Quizartinib,Cytarabine,Daunorubicin
Therapeutic Area: Oncology Brand Name: Vanflyta
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 09, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Quizartinib,Cytarabine,Daunorubicin
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
VANFLYTA® Approved in the EU as the First FLT3 Inhibitor Specifically for Patients with Newly Dia...
Details : VANFLYTA® (quizartinib) is an oral, highly potent, type II FLT3 inhibitor that selectively targets FLT3-ITD mutations and has been specifically developed for patients with FLT3-ITD positive AML.
Product Name : Vanflyta
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 09, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Vanflyta (quizartinib) is an oral, highly potent, type II FLT3 inhibitor that selectively targets FLT3-ITD mutations and has been specifically developed for patients with FLT3-ITD positive AML.
Lead Product(s): Quizartinib,Cytarabine,Daunorubicin
Therapeutic Area: Oncology Brand Name: Vanflyta
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 15, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Quizartinib,Cytarabine,Daunorubicin
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Vanflyta (quizartinib) is an oral, highly potent, type II FLT3 inhibitor that selectively targets FLT3-ITD mutations and has been specifically developed for patients with FLT3-ITD positive AML.
Product Name : Vanflyta
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 15, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
VANFLYTA® (quizartinib) is an oral, highly potent, type II FLT3 inhibitor that selectively targets FLT3-ITD mutations and has been specifically developed for patients with FLT3-ITD positive AML.
Lead Product(s): Quizartinib,Cytarabine,Daunorubicin
Therapeutic Area: Oncology Brand Name: Vanflyta
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 09, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Quizartinib,Cytarabine,Daunorubicin
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
VANFLYTA® Now Available in U.S. for Patients with Newly Diagnosed FLT3-ITD Positive AML
Details : VANFLYTA® (quizartinib) is an oral, highly potent, type II FLT3 inhibitor that selectively targets FLT3-ITD mutations and has been specifically developed for patients with FLT3-ITD positive AML.
Product Name : Vanflyta
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 09, 2023

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Approved
Registration Country : Sweden
Brand Name : Vanflyta
Dosage Form : Film Coated Tablet
Dosage Strength : 17.7mg
Packaging :
Approval Date : 06/11/2023
Application Number : 20220627000076
Regulatory Info : Approved
Registration Country : Sweden

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Approved
Registration Country : Sweden
Brand Name : Vanflyta
Dosage Form : Film Coated Tablet
Dosage Strength : 26.5mg
Packaging :
Approval Date : 06/11/2023
Application Number : 20220627000083
Regulatory Info : Approved
Registration Country : Sweden

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Allowed
Registration Country : Switzerland
Brand Name : VANFLYTA
Dosage Form : Film Coated Tablet
Dosage Strength : 20mg
Packaging :
Approval Date : 31/03/2025
Application Number : 69710
Regulatory Info : Allowed
Registration Country : Switzerland

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Allowed
Registration Country : Switzerland
Brand Name : VANFLYTA
Dosage Form : Film Coated Tablet
Dosage Strength : 30mg
Packaging :
Approval Date : 31/03/2025
Application Number : 69710
Regulatory Info : Allowed
Registration Country : Switzerland

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]https://www.pharmacompass.com/radio-compass-blog/fda-approvals-drop-24-in-h1-2025-gsk-s-uti-med-vertex-s-non-opioid-painkiller-lead-pack-of-first-in-class-meds
Global Sales Information
Patents & EXCLUSIVITIES
Patent Expiration Date : 2030-03-23
US Patent Number : 8836218
Drug Substance Claim :
Drug Product Claim :
Application Number : 216993
Patent Use Code : U-3661
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2030-03-23

Patent Expiration Date : 2027-03-16
US Patent Number : 8883783
Drug Substance Claim : Y
Drug Product Claim :
Application Number : 216993
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2027-03-16

Patent Expiration Date : 2031-02-26
US Patent Number : 8357690
Drug Substance Claim :
Drug Product Claim :
Application Number : 216993
Patent Use Code : U-3661
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2031-02-26

Patent Expiration Date : 2027-03-16
US Patent Number : 8883783
Drug Substance Claim : Y
Drug Product Claim :
Application Number : 216993
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2027-03-16

Patent Expiration Date : 2029-08-15
US Patent Number : 7968543
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 216993
Patent Use Code : U-3661
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2029-08-15

Patent Expiration Date : 2030-05-14
US Patent Number : 9555040
Drug Substance Claim :
Drug Product Claim :
Application Number : 216993
Patent Use Code : U-3661
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2030-05-14

Patent Expiration Date : 2027-03-16
US Patent Number : 8557810
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 216993
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2027-03-16

Patent Expiration Date : 2029-08-15
US Patent Number : 8865710
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 216993
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2029-08-15

Patent Expiration Date : 2030-03-23
US Patent Number : 8836218
Drug Substance Claim :
Drug Product Claim :
Application Number : 216993
Patent Use Code : U-3661
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2030-03-23

Patent Expiration Date : 2033-09-30
US Patent Number : 9675549
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 216993
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2033-09-30

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
67
PharmaCompass offers a list of Quizartinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Quizartinib manufacturer or Quizartinib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Quizartinib manufacturer or Quizartinib supplier.
PharmaCompass also assists you with knowing the Quizartinib API Price utilized in the formulation of products. Quizartinib API Price is not always fixed or binding as the Quizartinib Price is obtained through a variety of data sources. The Quizartinib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Quizartinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Quizartinib, including repackagers and relabelers. The FDA regulates Quizartinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Quizartinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Quizartinib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Quizartinib supplier is an individual or a company that provides Quizartinib active pharmaceutical ingredient (API) or Quizartinib finished formulations upon request. The Quizartinib suppliers may include Quizartinib API manufacturers, exporters, distributors and traders.
click here to find a list of Quizartinib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
Quizartinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Quizartinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Quizartinib GMP manufacturer or Quizartinib GMP API supplier for your needs.
A Quizartinib CoA (Certificate of Analysis) is a formal document that attests to Quizartinib's compliance with Quizartinib specifications and serves as a tool for batch-level quality control.
Quizartinib CoA mostly includes findings from lab analyses of a specific batch. For each Quizartinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Quizartinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Quizartinib EP), Quizartinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Quizartinib USP).